PMX Inc., led by CEO Kim Han-suk, which develops artificial intelligence diagnostic solutions, has succeeded in raising a Series A investment from Intervalue Partners, BNK Venture Investment, and Korea Alternative Investment.
Since its establishment in March 2020, the company has raised a total investment of 5 billion won ($4.2 million). PMX is a company that develops A.I. based solutions which diagnose Alzheimer's, Parkinson's, and lung diseases fast and efficiently using CT and MRI images including related biomarkers for chronic diseases.
The company has specialized technology for segmentation of MRI and CT images and is currently developing Chest CT, Brain and whole-body MRI solutions. These solutions perform following- Chest diagnostic solutions that provide segmentation and volume information to medical personnel by integrating X-Ray and CT images; Brain solutions that rapidly and accurately diagnose degenerative brain diseases such as Alzheimer's disease and Parkinson's disease by acquiring and reconstructing brain MRI, fMRI; and whole-body MRI data.
Currently, the target market is Korea and USA, therefore research team is incorporated in Seoul and Chicago. The Chicago branch is responsible for R&D, FDA approval, and distribution across United States.
Min Kyung-wan, team lead of Intervalue said, “It is an early-stage company, but unlike its competitors, PMX is unique as it will be developing medical AI solution for the global market as per FDA standards. PMX qualifies to be a global company considering it inhibits experience in US certification and additionally is led by successful collaborative history between CTO Girish Srinivasan and CEO Kim Han-suk.”
Kim Han-suk who also attended RSNA’2021, the world's largest radiological conference, said, "With the funds secured through this investment, we plan to improve the performance of A.I technologies under development and complete US licensing."
